Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00981799 · ClinicalTrials.gov registry record · Phase 1
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
A Phase 1 study, sponsored by Therapeutic Advances in Childhood Leukemia Consortium.
- Terminated
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT00981799 is a Phase 1 study that was terminated before completion, run by Therapeutic Advances in Childhood Leukemia Consortium. The registered enrollment target is 23 participants.
The verdict
NCT00981799, a Phase 1 study, was terminated before completion, sponsored by Therapeutic Advances in Childhood Leukemia Consortium.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
Nelarabine has shown significant activity in patients with T-cell malignancies. This study will determine the safety and maximum tolerated dose of the combination of nelarabine, cyclophosphamide and etoposide in patients with first bone marrow relapse of T-ALL, or first relapse of T-LL.
Interventions
- DRUG Cyclophosphamide
- DRUG Etoposide
- DRUG Methotrexate
- DRUG Filgrastim
- DRUG Nelarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2010-06 |
| Est. Completion | 2016-07-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00981799
The ClinicalTrials.gov registry entry for NCT00981799 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Therapeutic Advances in Childhood Leukemia Consortium, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00981799 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00981799 about?
NCT00981799 is a clinical study titled "Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL". Nelarabine has shown significant activity in patients with T-cell malignancies. This study will determine the safety and maximum tolerated dose of the combination of nelarabine, cyclophosphamide and etoposide in patients with first bone marrow relapse of T-ALL, or first relapse of T-LL.
What is the current status of trial NCT00981799?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2010-06. Estimated completion is 2016-07-18.
What interventions are being tested in trial NCT00981799?
The interventions under investigation include: Cyclophosphamide (DRUG), Etoposide (DRUG), Methotrexate (DRUG), Filgrastim (DRUG), Nelarabine (DRUG).
Who is sponsoring clinical trial NCT00981799?
This trial is sponsored by Therapeutic Advances in Childhood Leukemia Consortium, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.